Chemistry:ADX88178
From HandWiki
ADX88178 is an experimental drug that acts as a positive allosteric modulator for the glutamate receptor mGluR4. It was developed as a potential medication for the treatment of Parkinson's disease but had mixed results in animal studies, improving dyskinesia but worsening psychosis-like symptoms. However it has antiinflammatory effects in brain tissue which may make it useful for other indications.[1][2][3][4][5][6]
References
- ↑ "A potent and selective metabotropic glutamate receptor 4 positive allosteric modulator improves movement in rodent models of Parkinson's disease". The Journal of Pharmacology and Experimental Therapeutics 343 (1): 167–177. October 2012. doi:10.1124/jpet.112.196063. PMID 22787118.
- ↑ "Characterization of the novel positive allosteric modulator of the metabotropic glutamate receptor 4 ADX88178 in rodent models of neuropsychiatric disorders". The Journal of Pharmacology and Experimental Therapeutics 350 (3): 495–505. September 2014. doi:10.1124/jpet.114.214437. PMID 24947466.
- ↑ "The Metabotropic Glutamate Receptor 4 Positive Allosteric Modulator ADX88178 Inhibits Inflammatory Responses in Primary Microglia". Journal of Neuroimmune Pharmacology 11 (2): 231–237. June 2016. doi:10.1007/s11481-016-9655-z. PMID 26872456.
- ↑ "Putative mGluR4 positive allosteric modulators activate Gi-independent anti-inflammatory mechanisms in microglia". Neurochemistry International 138. September 2020. doi:10.1016/j.neuint.2020.104770. PMID 32454165.
- ↑ "Effect of the mGlu4 positive allosteric modulator ADX-88178 on parkinsonism, psychosis-like behaviours and dyskinesia in the MPTP-lesioned marmoset". Psychopharmacology 240 (10): 2093–2099. October 2023. doi:10.1007/s00213-023-06428-1. PMID 37516708.
- ↑ "Structural insights into dimerization and activation of the mGlu2-mGlu3 and mGlu2-mGlu4 heterodimers". Cell Research 33 (10): 762–774. October 2023. doi:10.1038/s41422-023-00830-2. PMID 37286794.
 |  |
